Cigar Companies Agree to Health Warnings on Products and Ads

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 8
Volume 9
Issue 8

WASHINGTON-The seven largest US cigar companies will place health warnings on their products and advertisements as the result of an agreement with the US Federal Trade Commission. The warnings read: “Cigar smoking can cause cancers of the mouth and throat, even if you do not inhale.” “Cigar smoking can cause lung cancer and heart disease.” “Tobacco use increases the risk of infertility, stillbirth, and low birth weight.” “Cigars are not a safe alternative to cigarettes.” “Tobacco smoke increases the risk of lung cancer and heart disease, even in nonsmokers.”

WASHINGTON—The seven largest US cigar companies will place health warnings on their products and advertisements as the result of an agreement with the US Federal Trade Commission. The warnings read: “Cigar smoking can cause cancers of the mouth and throat, even if you do not inhale.” “Cigar smoking can cause lung cancer and heart disease.” “Tobacco use increases the risk of infertility, stillbirth, and low birth weight.” “Cigars are not a safe alternative to cigarettes.” “Tobacco smoke increases the risk of lung cancer and heart disease, even in nonsmokers.”

Articles in this issue
Irinotecan Plus Cisplatin May Be a Promising Radiation Sensitizer, According to Phase II Study
Major Trial of Four Newest Chemotherapy Regimens for Advanced NSCLC Shows Comparable Survival
Irinotecan-Containing Chemotherapy Regimens Active in Pancreatic Cancer and Ovarian Cancer
Interim Results Show Similar Response Rates for TEC vs CEV in Small-Cell Lung Cancer
Scientists Identify Gene Mutations in Multiple Myeloma
Irinotecan Plus Cisplatin Results in Highly Significant Survival Improvement in Extensive-Disease Small-Cell Lung Cancer
New Analyses Establish the Addition of Irinotecan to Fluorouracil/Leucovorin as the New Standard of Care for First-Line Rx of Metastatic Colorectal Cancer
Single-Agent Herceptin Active in Metastatic Breast Cancer
Brain Metastases Respond to Paclitaxel, Carboplatin, and Brain RT
AC Comparable to CMF in ER-Negative, Node-Negative Early-Stage Breast Cancer
Herceptin/Vinorelbine Promising in Metastatic Breast Cancer
Early Phase III Results Indicate Concurrent Chemoradiation Is Promising for Treatment of Locally Advanced NSCLC
Gemcitabine/Vinorelbine Boosts Survival in Elderly NSCLC Patients
Timing Affects Chemotherapy’s Effectiveness and Tolerability in Metastatic Colon Cancer
Virtual Colonoscopy Promising for Colon Cancer Screening

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
Video 4 - "Frontline Treatment for EGFR-Mutated Lung Cancer"
Related Content
Surufatinib/Toripalimab Shows Encouraging Activity in NSCLC and SCLC

Surufatinib/Toripalimab Shows Encouraging Activity in NSCLC and SCLC

Tim Cortese
April 8th 2025
Article

Surufatinib/toripalimab elicited an ORR of 57.1% in patients with treatment-naïve NSCLC and 15.8% in patients with pretreated SCLC in a phase 2 trial.

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

AI, Immunotherapy, More Key Lung Cancer Advances Highlighted at 2025 ELCC

AI, Immunotherapy, More Key Lung Cancer Advances Highlighted at 2025 ELCC

Ariana Pelosci
April 1st 2025
Article

An expert panel at ELCC 2025 reviews the MARIPOSA trial's implications for first-line therapy in EGFR-mutated NSCLC and broader advancements.

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Achieving Health Equity in Lung Cancer Surgery

Rian M. Hasson Charles, MD, MPH, FACS
April 1st 2024
Podcast

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Patients with driver gene–negative non–small cell lung cancer who received immunotherapy beyond progression experienced better survival outcomes.

Continuous Second-Line Immunotherapy May Benefit Pretreated Lung Cancer

Roman Fabbricatore
March 6th 2025
Article

Patients with driver gene–negative non–small cell lung cancer who received immunotherapy beyond progression experienced better survival outcomes.

AI/ML-Based Software Improves Diagnostic Accuracy in Lung Cancer

AI/ML-Based Software Improves Diagnostic Accuracy in Lung Cancer

Tim Cortese
February 5th 2025
Article

The diagnostic accuracy of radiologists aided by the eyonis LCS AI software was greatly improved compared with when radiologists were unaided.